Literature DB >> 17054470

Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area.

Ki-wook Chung1, Sun Kyung Yang, Geon Kook Lee, Eun Young Kim, Soim Kwon, Sang Hyun Lee, Do Joon Park, Hyun Sook Lee, Bo Youn Cho, Eun Sook Lee, Sun Wook Kim.   

Abstract

BACKGROUND: Between 10 and 30% of the fine needle aspiration biopsies (FNABs) of thyroid nodules are diagnosed as 'indeterminate'. A molecular diagnostic method is needed to reduce unnecessary surgery in this group. In Korea, most thyroid cancer is the classic papillary type and the BRAF(V600E) mutation is highly prevalent. AIM: To evaluate the role of pre-operative detection of BRAF(V600E) mutation in the FNAB specimens of thyroid nodules in a BRAF(V600E) mutation-prevalent geographical area. PATIENTS AND METHODS: In 137 specimens of FNAB (107 papillary thyroid carcinomas (PTC); 3 follicular thyroid carcinomas (FTC); 2 undifferentiated thyroid carcinomas; 25 benign lesions), both direct DNA sequencing and PCR-RFLP were used for detecting the BRAF(V600E) mutation. The sensitivity and specificity were calculated. We analysed the association between BRAF(V600E) mutation and the clinico-pathological parameters.
RESULTS: The BRAF(V600E) mutation was present in 93 (83%) of 112 thyroid cancers. Direct DNA sequencing showed a sensitivity of 83.0% and a specificity of 96.0%. The sensitivity and specificity of PCR-RFLP were 78.6% and 80.0%, respectively. Among 25 cases with indeterminate FNAB cytology, 8 patients had malignant lesions (5 PTC and 3 FTC). Three (60%) of 5 PTCs and 1 out of 17 benign lesions had BRAF(V600E) mutation (only one false positive case and the definitive pathology showed atypical nodular hyperplasia that could be a premalignant lesion). The diagnostic accuracy of this molecular method in only the 25 indeterminate nodules was 76% (19/25). No mutation was found in 3 FTCs. Among 107 PTCs, there was no significant association of the BRAF(V600E) mutation with the known risk factors.
CONCLUSION: Detection of the BRAF(V600E) mutation in FNAB specimens refines the FNAB-cytology diagnosis, especially in a BRAF(V600E) mutation-prevalent area. Direct DNA sequencing was a more reliable method than PCR-RFLP for detecting the BRAF(V600E) mutation with a high sensitivity and specificity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17054470     DOI: 10.1111/j.1365-2265.2006.02646.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  42 in total

1.  Search for genetic mutations in cytological samples from thyroid nodules as a diagnostic tool: reality, hope or myth?

Authors:  F Pacini; S Cantara; M Capezzone
Journal:  J Endocrinol Invest       Date:  2010-09       Impact factor: 4.256

2.  Lysyl Oxidase Is a Key Player in BRAF/MAPK Pathway-Driven Thyroid Cancer Aggressiveness.

Authors:  Myriem Boufraqech; Dhaval Patel; Naris Nilubol; Astin Powers; Timothy King; Jasmine Shell; Justin Lack; Lisa Zhang; Sudheer Kumar Gara; Viswanath Gunda; Joanna Klubo-Gwiezdzinska; Suresh Kumar; James Fagin; Jeffrey Knauf; Sareh Parangi; David Venzon; Martha Quezado; Electron Kebebew
Journal:  Thyroid       Date:  2018-12-28       Impact factor: 6.568

Review 3.  Molecular pathology of thyroid cancer: diagnostic and clinical implications.

Authors:  James A Fagin; Nicholas Mitsiades
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2008-12       Impact factor: 4.690

4.  Additional BRAF mutation analysis may have additional diagnostic value in thyroid nodules with "suspicious for malignant" cytology alone even when the nodules do not show suspicious US features.

Authors:  Jae Young Seo; Eun-Kyung Kim; Jin Young Kwak
Journal:  Endocrine       Date:  2014-01-23       Impact factor: 3.633

5.  BRAF and RAS mutations in follicular variants of papillary thyroid carcinoma.

Authors:  Ji Young Park; Wook Youn Kim; Tae Sook Hwang; Sang Sook Lee; Hyunkyung Kim; Hye Seung Han; So Dug Lim; Wan Seop Kim; Young Bum Yoo; Kyoung Sik Park
Journal:  Endocr Pathol       Date:  2013-06       Impact factor: 3.943

Review 6.  Values of molecular markers in the differential diagnosis of thyroid abnormalities.

Authors:  T M P B Tennakoon; M Rushdhi; A D C U Ranasinghe; R S Dassanayake
Journal:  J Cancer Res Clin Oncol       Date:  2016-12-22       Impact factor: 4.553

7.  BRAF V600E mutation in papillary thyroid carcinoma: significant association with node metastases and extra thyroidal invasion.

Authors:  Avik Chakraborty; Archana Narkar; Rita Mukhopadhyaya; Shubhada Kane; Anil D'Cruz; M G R Rajan
Journal:  Endocr Pathol       Date:  2012-06       Impact factor: 3.943

8.  Thyroid cancer: current molecular perspectives.

Authors:  Francesca Giusti; Alberto Falchetti; Francesco Franceschelli; Francesca Marini; Annalisa Tanini; Maria Luisa Brandi
Journal:  J Oncol       Date:  2010-03-29       Impact factor: 4.375

9.  Does papillary thyroid carcinoma have a better prognosis with or without Hashimoto thyroiditis?

Authors:  Hee Yong Kwak; Byung Joo Chae; Yong Hwa Eom; Young Ran Hong; Jae Beom Seo; So Hee Lee; Byung Joo Song; Sang Seol Jung; Ja Seong Bae
Journal:  Int J Clin Oncol       Date:  2014-10-15       Impact factor: 3.402

10.  Molecular detection of PPAR gamma rearrangements and thyroid carcinoma in preoperative fine-needle aspiration biopsies.

Authors:  Christopher A French; Jonathan A Fletcher; Edmund S Cibas; Christopher Caulfield; Paulette Allard; Todd G Kroll
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.